Download Poster (266 KB)
- Patients living with HIV (PLWH) are at high risk for atherosclerotic cardiovascular disease (ASCVD)
- Eligible PLWH should receive statins for ASCVD risk reduction according to current guidelines
- Studies suggest that statins are underprescribed in PLWH, but comparisons to uninfected patients and assessments of statin intensity have not occurred
To determine the influence of HIV infection on appropriate statin prescribing for ASCVD risk reduction
HIV, cardiovascular disease
Cardiology | Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
Schafer, PharmD, MPH, Jason J.; Emmons, PharmD, BCPS, Roshni; Hastain, PharmD, Nick V.; and Miano, PharmD, PhD, Todd, "Patients living with HIV infection are less likely to receive the correct statin intensity for cardiovascular disease risk reduction" (2019). College of Pharmacy Posters. 18.